Julio C Rojas

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3021913/publications.pdf

Version: 2024-02-01

430442 476904 3,304 31 18 29 citations h-index g-index papers 32 32 32 5095 docs citations times ranked citing authors all docs

#	Article	IF	Citations
1	Lower White Matter Volume and Worse Executive Functioning Reflected in Higher Levels of Plasma GFAP among Older Adults with and Without Cognitive Impairment. Journal of the International Neuropsychological Society, 2022, 28, 588-599.	1.2	14
2	Comprehensive cross-sectional and longitudinal analyses of plasma neurofilament light across FTD spectrum disorders. Cell Reports Medicine, 2022, 3, 100607.	3.3	21
3	Visual Impairment as a Modifiable Risk Factor in Dementia Prevention and Management. JAMA Neurology, 2022, 79, 542.	4.5	2
4	Diagnostic Accuracy of Magnetic Resonance Imaging Measures of Brain Atrophy Across the Spectrum of Progressive Supranuclear Palsy and Corticobasal Degeneration. JAMA Network Open, 2022, 5, e229588.	2.8	18
5	Sensitivity of the Social Behavior Observer Checklist to Early Symptoms of Patients With Frontotemporal Dementia. Neurology, 2022, , 10.1212/WNL.00000000000200582.	1.5	O
6	Plasma P-tau181 and P-tau217 in Patients With Traumatic Encephalopathy Syndrome With and Without Evidence of Alzheimer Disease Pathology. Neurology, 2022, 99, .	1.5	10
7	Plasma Neurofilament Light for Prediction of Disease Progression in Familial Frontotemporal Lobar Degeneration. Neurology, 2021, 96, e2296-e2312.	1.5	52
8	Selective vulnerability to atrophy in sporadic Creutzfeldtâ€Jakob disease. Annals of Clinical and Translational Neurology, 2021, 8, 1183-1199.	1.7	4
9	Effect of the Histone Deacetylase Inhibitor FRM-0334 on Progranulin Levels in Patients With Progranulin Gene Haploinsufficiency. JAMA Network Open, 2021, 4, e2125584.	2.8	18
10	Plasma phosphorylated tau 217 and phosphorylated tau 181 as biomarkers in Alzheimer's disease and frontotemporal lobar degeneration: a retrospective diagnostic performance study. Lancet Neurology, The, 2021, 20, 739-752.	4.9	220
11	Plasma Tau and Neurofilament Light in Frontotemporal Lobar Degeneration and Alzheimer Disease. Neurology, 2021, 96, e671-e683.	1.5	84
12	4-Repeat tau seeds and templating subtypes as brain and CSF biomarkers of frontotemporal lobar degeneration. Acta Neuropathologica, 2020, 139, 63-77.	3.9	89
13	Reactions to Multiple Ascending Doses of the Microtubule Stabilizer TPI-287 in Patients With Alzheimer Disease, Progressive Supranuclear Palsy, and Corticobasal Syndrome. JAMA Neurology, 2020, 77, 215.	4.5	81
14	Promoting tau secretion and propagation by hyperactive p300/CBP via autophagy-lysosomal pathway in tauopathy. Molecular Neurodegeneration, 2020, 15, 2.	4.4	69
15	Prospective longitudinal atrophy in Alzheimer's disease correlates with the intensity and topography of baseline tau-PET. Science Translational Medicine, 2020, 12, .	5.8	353
16	Four-Repeat Tauopathies: Current Management and Future Treatments. Neurotherapeutics, 2020, 17, 1563-1581.	2.1	24
17	Plasma Glial Fibrillary Acidic Protein Levels Differ Along the Spectra of Amyloid Burden and Clinical Disease Stage1. Journal of Alzheimer's Disease, 2020, 78, 265-276.	1.2	43
18	Diagnostic value of plasma phosphorylated tau181 in Alzheimer's disease and frontotemporal lobar degeneration. Nature Medicine, 2020, 26, 387-397.	15.2	471

#	Article	IF	CITATIONS
19	<scp>Openâ€Label /scp> Phase 1 Futility Studies of Salsalate and Young Plasma in Progressive Supranuclear Palsy. Movement Disorders Clinical Practice, 2020, 7, 440-447.</scp>	0.8	34
20	Peripheral Innate Immune Activation Correlates With Disease Severity in GRN Haploinsufficiency. Frontiers in Neurology, 2019, 10, 1004.	1.1	7
21	Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology. JAMA Neurology, 2019, 76, 1035.	4.5	455
22	Association of Blood and Cerebrospinal Fluid Tau Level and Other Biomarkers With Survival Time in Sporadic Creutzfeldt-Jakob Disease. JAMA Neurology, 2019, 76, 969.	4.5	65
23	CSF neurofilament light chain and phosphorylated tau 181 predict disease progression in PSP. Neurology, 2018, 90, e273-e281.	1.5	75
24	Multiproteinopathy, neurodegeneration and old age: a case study. Neurocase, 2018, 24, 1-6.	0.2	2
25	F2â€02â€02: NEUROFILAMENT LIGHT CHAIN AS A BIOMARKER FOR FRONTOTEMPORAL LOBAR DEGENERATION. Alzheimer's and Dementia, 2018, 14, P603.	0.4	O
26	Cerebrospinal fluid biomarkers predict frontotemporal dementia trajectory. Annals of Clinical and Translational Neurology, 2018, 5, 1250-1263.	1.7	40
27	ApoE4 markedly exacerbates tau-mediated neurodegeneration in a mouse model of tauopathy. Nature, 2017, 549, 523-527.	13.7	852
28	Genetic Prion Disease Caused by PRNP Q160X Mutation Presenting with an Orbitofrontal Syndrome, Cyclic Diarrhea, and Peripheral Neuropathy. Journal of Alzheimer's Disease, 2016, 55, 249-258.	1.2	13
29	Plasma neurofilament light chain predicts progression in progressive supranuclear palsy. Annals of Clinical and Translational Neurology, 2016, 3, 216-225.	1.7	163
30	Targeting tauopathies for therapeutic translation. Nature Reviews Neurology, 2016, 12, 74-76.	4.9	21
31	Non-amnestic mild cognitive impairment. , 2016, , 232-244.		1